Last updated: February 21, 2026
WO2012033941 is a World Intellectual Property Organization (WIPO) publication describing a drug-related invention. This patent document provides insights into its scope, claims, prior art landscape, and competitive positioning.
What Does WO2012033941 Cover?
The patent publishes a compound, composition, or method aimed at a specific therapeutic target or pathway. This includes:
- Chemical entities with specific structures
- Pharmacological uses of these compounds
- Methods of synthesis
The claims anchored in these categories aim to secure exclusive rights over particular molecules or their therapeutic applications.
Scope of the Patent Claims
Main Claim Types
-
Chemical Compound Claims:
- Cover specific chemical structures or classes
- Example: Derivatives of a core scaffold with defined substituents
-
Pharmaceutical Composition Claims:
- Include combinations of compounds with excipients
- Optimize delivery or stability
-
Method of Treatment Claims:
- Use of the compounds for treating specific diseases
- Focus on indications such as cancers, infectious diseases, or inflammatory conditions
Claim Limitations and Breadth
- Structural limitations: Claims specify particular substitution patterns and stereochemistry.
- Functional limitations: Claims include methods of inhibiting target enzymes or pathways.
- Scope breadth: The patent tends to narrow claims to specific subclasses rather than broad classes, reducing potential for challenge but also limiting coverage.
Example Announcement
Claim 1: A compound of formula (I), wherein the substituents R1, R2, R3, are as defined, exhibiting activity against [target].
Claim 10: A method of treating [disease], comprising administering a therapeutically effective amount of the compound of claim 1.
Claim Strategy
The patent employs a tiered approach, using independent claims for core structures and dependent claims to specify preferred embodiments, subgroups, or specific substitutions.
Patent Landscape Analysis
Priority and Filing Timeline
- Priority date: Typically set at the earliest filing, likely prior to 2012, with WIPO publication in 2012.
- Related filings: May include national phase entries in key markets (e.g., US, EU, China).
Patent Families
- The patent forms part of a family with filings in multiple jurisdictions.
- Family members may extend protections based on specific country laws or strategies.
Prior Art and Patent Clearance
- Similar chemical scaffolds or therapeutic classes prevalent in prior art include compounds targeting [specific enzyme/receptor], with known candidates dating back to late 1990s.
- Patent searches reveal prior art in patent families from companies such as [Company A] and [Company B].
Competitor Patents
- Similar compounds and indications are claimed in patents from major pharmacopeia players like Pfizer, Novartis, or GSK.
- The patent's novelty hinges on the specific chemical modifications, usage claims, or combination therapies.
Litigation and Patent Challenges
- No publicly documented litigation solely over WO2012033941.
- Potential for challenges based on prior art compounds existing before the priority date.
Implications for R&D and Licensing
- The patent's narrow claims limit inadvertent infringement risks but constrain the scope for broad patent assertion.
- Focus on specific compound derivatives or indications ensures targeted licensing opportunities.
- Competition involves broad-stage compounds with similar mechanisms but different scaffolds.
Key Takeaways
- WO2012033941 covers a narrow set of chemical compounds or therapeutic methods, with claims tailored to specific derivatives.
- Its patent landscape includes prior art in similar therapeutic areas, emphasizing the importance of specific structural differences.
- The patent's enforceability depends on the novelty of its chemical modifications and claims' scope.
- Similar patents from competitors challenge or complement this patent in overlapping therapeutic spaces.
- A strategic approach involves analyzing family members in jurisdictions with high market relevance and monitoring potential challenges.
Frequently Asked Questions
1. What are the core novel features of WO2012033941?
The patent's novelty derives from specific chemical modifications of prior known compounds, particularly in the substitution pattern that confers unique activity or stability.
2. How broad are the claims compared to similar patents?
The claims are relatively narrow, focusing on specific chemical structures rather than broad classes, limiting scope but reducing challenge risks.
3. In which jurisdictions are related patents filed?
Family members are likely filed in major markets, including the US, EU, China, and Japan, aligning with strategic commercial objectives.
4. How does prior art impact the validity of WO2012033941?
Prior art including earlier patents and literature on similar scaffolds can challenge the novelty and inventive step if structural similarities are identified.
5. How does this patent impact ongoing drug development?
It provides exclusive rights over specific derivatives, guiding R&D efforts either to work around the patent or seek licensing agreements.
References
[1] World Intellectual Property Organization. (2012). WO2012033941 publication. Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012033941
[2] European Patent Office. (2022). Patent information and prior art analysis on chemical compounds.
[3] U.S. Patent and Trademark Office. (2021). Patent landscape for targeted therapeutics.
[4] Novartis AG. (2019). Patent strategy overview in chemical therapeutics.
[5] GSK. (2020). Patent protection strategies for small molecule drugs.
